J
Jean François Delfraissy
Researcher at University of Paris-Sud
Publications - 38
Citations - 9265
Jean François Delfraissy is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Pregnancy & Zidovudine. The author has an hindex of 27, co-authored 38 publications receiving 9097 citations. Previous affiliations of Jean François Delfraissy include University of Paris & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
Edward M. Connor,Rhoda S. Sperling,Richard D. Gelber,Pavel Kiselev,Gwendolyn B. Scott,Mary Jo O'Sullivan,Russell Vandyke,Mohammed Bey,William T. Shearer,Robert L. Jacobson,Eleanor Jimenez,Edward O’neill,Brigitte Bazin,Jean François Delfraissy,Mary Culnane,Robert W. Coombs,Mary Elkins,Jack Moye,Pamela Stratton,James Balsley +19 more
TL;DR: In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds.
Journal ArticleDOI
Reduction of maternal-infant transmission of human immunodeficiency virus 1 with zidovudine treatment
Edward M. Connor,Rhoda S. Sperling,Richard D. Gelber,Pavel Kiselev,Gwendolyn B. Scott,Mary J. O'Sullivan,Russell Vandyke,Mohammed Bey,William T. Shearer,R Jacobson,Eleanor Jimenez,Edward O’neill,Brigitte Bazin,Jean François Delfraissy,Mary Culnane,Robert W. Coombs,Mary Elkins,Jack Moye,Pamela Stratton,James Balsley +19 more
TL;DR: It was shown that AZT decreased the maternal-infant transmission of HIV and helped decrease infant mortality due to the viral infection.
Journal ArticleDOI
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Adriano Lazzarin,Bonaventura Clotet,David A. Cooper,Jacques Reynes,Keikawus Arastéh,Mark Nelson,Christine Katlama,Hans Jürgen Stellbrink,Jean François Delfraissy,Joep M. A. Lange,Les Huson,Ralph DeMasi,Cynthia Wat,John Delehanty,Claude Drobnes,Miklos Salgo +15 more
TL;DR: The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) as discussed by the authors compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy of the optimized background regimen alone.
Journal ArticleDOI
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Alejandro Dorenbaum,Coleen K. Cunningham,Richard D. Gelber,Mary Culnane,Lynne M. Mofenson,Paula Britto,Claire Rekacewicz,Marie-Louise Newell,Jean François Delfraissy,Bethann Cunningham-Schrader,Mark Mirochnick,John L. Sullivan +11 more
TL;DR: A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency virus (HIV) transmission in Ugandan women not receiving antenatalantiretroviral therapy (ART).
Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission
Alejandro Dorenbaum,Coleen K. Cunningham,Richard D. Gelber,Mary Culnane,Lynne M. Mofenson,Paula Britto,Marie-Louise Newell,Jean François Delfraissy,Bethann Cunningham-Schrader,John L. Sullivan +9 more
TL;DR: Risk of perinatal HIV transmission was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when women received prenatal care and antenatal ART, and elective cesarean section was made available.